A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2027

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Cusatuzumab

CD70 monoclonal antibody

DRUG

Venetoclax

BCL-2 inhibitor

DRUG

Azacitidine

Hypomethylating agent

Trial Locations (31)

3010

RECRUITING

Inselspital Bern, Bern

9007

RECRUITING

Kantonsspital St. Gallen, Sankt Gallen

10065

RECRUITING

Cornell University, New York

11042

RECRUITING

Hofstra/Northwell Health, Lake Success

14642

RECRUITING

University of Rochester Medical Center, Rochester

24105

RECRUITING

Universitaetsklinik um Schleswig-Holstein, UKSH-Campus Kiel, Kiel

27157

NOT_YET_RECRUITING

Wake Forest North Carolina, Winston-Salem

29425

RECRUITING

Medical University of South Carolina, Charleston

30625

RECRUITING

Medizinische Hochschule Hanover, Hannover Medical School, Hanover

32804

RECRUITING

AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando

40202

RECRUITING

Norton Healthcare, Inc., Louisville

40479

RECRUITING

Marien Hospital Duesseldorf, Düsseldorf

40536

RECRUITING

University of Kentucky Chandler Medical Center, Lexington

52242

RECRUITING

The University of Iowa Hospitals & Clinics, Iowa City

53226

NOT_YET_RECRUITING

Medical College of Wisonsin, Milwaukee

60560

RECRUITING

Universitaetsklinik Frankfurt, Frankfurt

80045

RECRUITING

University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus, Aurora

85234

RECRUITING

Banner MD Anderson, Gilbert

90095

RECRUITING

University of California Los Angeles, Los Angeles

91010

RECRUITING

City of Hope, Duarte

98109

RECRUITING

Fred Hutch Seattle Cancer Care Alliance, Seattle

06510

RECRUITING

Yale School of Medicine, New Haven

07601

NOT_YET_RECRUITING

Hackensack University Medical Center, Hackensack

T2N 4N2

RECRUITING

Tom Baker Cancer Center-Alberta Health Services - University of Calgary, Calgary

T6G 2B7

RECRUITING

Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta, Edmonton

V5Z 1M9

RECRUITING

Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre, Vancouver

N6A5W9

RECRUITING

University of Western Ontario, London

K1H8L6

RECRUITING

The Ottawa Hospital - General Campus, Ottawa

M5F 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

S7N4H4

RECRUITING

Saskatchewan Cancer Agency - Saskatoon Cancer Centre, Saskatoon

Switzerland

RECRUITING

HFR Fribourg - Hopital Cantonal, Fribourg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

OncoVerity, Inc.

INDUSTRY

NCT06384261 - A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Biotech Hunter | Biotech Hunter